Form 4: BioCryst Pharmaceuticals Executive Receives Stock Options and Restricted Stock Units

Helen M. Thackray, Chief R&D Officer of BioCryst Pharmaceuticals, reports acquisition of stock options and restricted stock units, along with shares withheld for tax obligations.

Summary

• Helen M. Thackray, Chief R&D Officer at BioCryst Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• On December 19, 2024, Thackray received an annual award of 125,950 Restricted Stock Units (RSUs) that will vest 25% annually over four years.
• Also on December 19, 2024, Thackray was granted an employee stock option to buy 260,950 shares at an exercise price of $7.39, vesting 25% annually over four years, expiring on December 19, 2034.
• 6,096 shares were withheld by BioCryst to cover tax obligations related to the vesting of previously granted RSUs at a price of $7.39 per share.
• Following these transactions, Thackray directly owns 384,843 shares of BioCryst Pharmaceuticals.
• She also holds options to purchase 260,950 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The equity grants indicate confidence in the executive and the company's future, but the tax withholding is a minor negative.

Positives

• The grant of RSUs and stock options to a key executive like the Chief R&D Officer suggests an incentive alignment with the company's long-term performance.
• The vesting schedule of both the RSUs and stock options encourages continued service and commitment from the executive.

Negatives

• The withholding of shares to cover tax obligations, while standard practice, reduces the number of shares the executive ultimately receives.

Risks

• The value of the stock options is dependent on the future performance of BioCryst's stock; if the stock price does not exceed the exercise price of $7.39, the options will be worthless.
• The vesting schedule means the executive must remain with the company to fully realize the value of the RSUs and stock options.

Future Outlook

The document does not contain explicit forward-looking statements, but the equity grants suggest an expectation of future value creation at BioCryst.

Industry Context

Equity grants are a common practice in the pharmaceutical industry to incentivize and retain key executives. The size and vesting schedule of these grants are generally aligned with industry benchmarks for similar roles and company size.

Comparison to Industry Standards

• Equity compensation for R&D executives in biotech companies typically includes a mix of stock options and restricted stock units.
• The vesting schedules (25% annually over four years) are standard in the industry to ensure long-term alignment.
• Comparable companies like Argenx and Vertex Pharmaceuticals also utilize similar equity-based compensation structures for their executive teams.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align executive interests with company performance.
• Employees may see the grants as a sign of the company's commitment to its leadership.

Key Dates